In vitro detection of contact allergens: Development of an optimized protocol using human peripheral blood monocyte-derived dendritic cells

• Published in: Toxicology in vitro 2011-02, Vol.25 (1), p.315-323
• Main Authors: Reuter, Hendrik, Spieker, Jochem, Gerlach, Silke, Engels, Ursula, Pape, Wolfgang, Kolbe, Ludger, Schmucker, Robert, Wenck, Horst, Diembeck, Walter, Wittern, Klaus-Peter, Reisinger, Kerstin, Schepky, Andreas G.
• Format: Article
• Language: English
• Subjects: Allergens; Allergens - toxicity; Alternative method; Animal Testing Alternatives; B7-2 Antigen - metabolism; CD86; Cell Differentiation; Cell Separation - methods; Cell Survival - drug effects; Cells, Cultured; Cosmetics - toxicity; Cytokines - pharmacology; Dendritic cell; Dendritic Cells - drug effects; Dendritic Cells - immunology; Dendritic Cells - metabolism; Dermatitis, Allergic Contact - prevention & control; Flow Cytometry; Haptens - immunology; Humans; In vitro toxicology; Lipopolysaccharide Receptors - metabolism; Monocytes - cytology; Reproducibility of Results; Sensitization; Toxicity Tests - methods
• ISSN: 0887-2333; 1879-3177
• DOI: 10.1016/j.tiv.2010.09.016

Allergic contact dermatitis is a delayed T-cell mediated allergic response associated with relevant social and economic impacts. Animal experiments (e.g. the local lymph node assay) are still supplying most of the data used to assess the sensitization potential of new chemicals. However, the 7th amendment to the EU Cosmetic Directive will introduce a testing ban for cosmetic ingredients after 2013. In vitro alternative methods are thus being actively developed. Although promising results have been obtained with cell lines, their reduced functionality and inherent genomic instability led us to reinvestigate the use of peripheral blood monocyte-derived dendritic cells (PBMDCs) for the establishment of a reliable in vitro sensitization test. To solve the issues associated with the use of primary cells, the culture and exposure conditions (cytokine concentrations, incubation time, readout, pooled vs. single donors and cytotoxicity) were re-assessed and optimized. Here we propose a stable and reproducible protocol based on PBMDCs. This should allow a wider acceptance of PBMDCs as a reliable test system for the detection of human skin sensitizers and the inclusion of this protocol in an integrated testing strategy.